Histone	O
Deacetylase	O
Inhibitors	O
Repress	O
Tumoral	O
Expression	O
of	O
the	O
Proinvasive	O
Factor	O
RUNX2	O
.	O


Aberrant	O
reactivation	O
of	O
embryonic	O
pathways	O
occurs	O
commonly	O
in	O
cancer	S-DISEASE
.	O


The	O
transcription	O
factor	O
RUNX2	O
plays	O
a	O
fundamental	O
role	O
during	O
embryogenesis	O
and	O
is	O
aberrantly	O
reactivated	O
during	O
progression	O
and	O
metastasization	O
of	O
different	O
types	O
of	O
human	O
tumors	S-DISEASE
.	O


In	O
this	O
study	O
,	O
we	O
attempted	O
to	O
dissect	O
the	O
molecular	O
mechanisms	O
governing	O
RUNX2	O
expression	O
and	O
its	O
aberrant	O
reactivation	O
.	O


We	O
identified	O
a	O
new	O
regulatory	O
enhancer	O
element	O
,	O
located	O
within	O
the	O
RUNX2	O
gene	O
,	O
which	O
is	O
responsible	O
for	O
the	O
activation	O
of	O
the	O
RUNX2	O
promoter	O
and	O
for	O
the	O
regulation	O
of	O
its	O
expression	O
in	O
cancer	O
cells	O
.	O


Furthermore	O
,	O
we	O
have	O
shown	O
that	O
treatment	O
with	O
the	O
anticancer	O
compounds	O
histone	O
deacetylase	O
inhibitor	O
(	O
HDACi	O
)	O
results	O
in	O
a	O
profound	O
inhibition	O
of	O
RUNX2	O
expression	O
,	O
which	O
is	O
determined	O
by	O
the	O
disruption	O
of	O
the	O
transcription	O
-	O
activating	O
complex	O
on	O
the	O
identified	O
enhancer	O
.	O


These	O
data	O
envisage	O
a	O
possible	O
targeting	O
strategy	O
to	O
counteract	O
the	O
oncongenic	O
function	O
of	O
RUNX2	O
in	O
cancer	S-DISEASE
cells	O
and	O
provide	O
evidence	O
that	O
the	O
cytotoxic	O
activity	O
of	O
HDACi	O
in	O
cancer	O
is	O
not	O
only	O
dependent	O
on	O
the	O
reactivation	O
of	O
silenced	O
oncosuppressors	O
but	O
also	O
on	O
the	O
repression	O
of	O
oncogenic	O
factors	O
that	O
are	O
necessary	O
for	O
survival	O
and	O
progression	O
.	O
